MODI Algorithm for Type 1 Diabetes

(MODIUS Trial)

This trial tests a new tool called the MODI algorithm, designed to assist people with type 1 diabetes (T1D) who manage their condition with multiple daily insulin injections and continuous glucose monitoring. The researchers aim to determine if the MODI algorithm is safe for this group. The study lasts 13 weeks, following a 2-week period on standard therapy. Ideal participants are adults who have lived with T1D for at least six months, use insulin injections daily, and continuously monitor their glucose levels. Participants must also agree to use specific smartphone apps to record daily activities and insulin use. As an unphased trial, this study offers a unique opportunity to contribute to innovative diabetes management research.

The trial does not specify that you must stop taking your current medications. However, your doses of non-insulin glucose-lowering and weight loss medications should be stable for 4 weeks before the trial and are not expected to change during the study, unless for safety reasons.

Research has shown that the MODI Algorithm, which helps adjust insulin doses for people with type 1 diabetes, has undergone previous study. These studies suggest it is safe to use. For instance, one study tested a similar digital tool for adjusting insulin in people with type 2 diabetes and found it to be a safe way to manage insulin doses.

The MODI Algorithm is unique because it offers a personalized approach to managing Type 1 Diabetes by using an advanced algorithm for insulin titration. Unlike standard treatments that often rely on manual adjustments of insulin doses, this algorithm-driven method aims to optimize insulin dosing more efficiently and accurately. Researchers are excited about this treatment because it has the potential to reduce the guesswork in insulin management, potentially leading to better blood sugar control and improved quality of life for patients.

Research has shown that the MODI Algorithm, which adjusts insulin doses for people with type 1 diabetes, is promising. One study found that using this algorithm increased the time patients maintained their blood sugar within the target range from 64% to 77% and significantly reduced the time they experienced low blood sugar. Another study reported that patients using the MODI Algorithm had an average HbA1c level of 6.58%, with most staying below the target level. These findings suggest that the MODI Algorithm can effectively help manage blood sugar levels in type 1 diabetes. Participants in this trial will receive guidance on insulin titration using the MODI Algorithm.¹⁶⁷⁸⁹